The prostate-reducing drug that Donald Trump uses to treat hair loss has been linked to an increased risk of depression, self-harm and erectile dysfunction.
Finasteride is a widely-used drug that reduces the size of prostate glands and stimulates hair growth – and is widely believed to be a significant factor affecting the president’s low PSA (prostate) levels and thick mane.
However, it has been tied to many severe and uncomfortable side effects.
A research paper published in March 2017 by Western University in Ontario offered the first concrete evidence showing the pills’ mental health risks, and appeared to confirm many medics’ fears that it increases a risk of suicidal tendencies.
The same week, a study by Northwestern University Feinberg School of Medicine found most study participants were left impotent for four years after taking Propecia (the brand name for finasteride).
Finasteride, a widely-used drug that reduces prostate glands and stimulates hair growth, increased risk of depression by 94 percent in the first 18 months, a study by Western University found. Another study by Northwestern University found it causes erectile issues
Finasteride belongs to a class of medications known as 5-alpha-reductase inhibitors (5ARIs).
5ARIs have come under increasing scrutiny in recent years by regulators in the United States and Canada because of a possible link to mental health issues, according to the researchers.
Finasteride was originally developed to treat urinary problems in men.
Studies showed the drug made prostate glands smaller by reducing the levels of the hormone dihydrotestosterone in participants.
But during the clinical trials, scientists saw an unexpected side effect – hair growth.
And so in 1997, the FDA approved the steroid inhibitor as the first ever drug to treat male pattern baldness.
Taken once a day, the drug is mainly sold under the brand name Propecia. Millions of American adults use the pills, which are proven to be 90 percent effective.
In February 2017, Donald Trump’s doctor Harold Bornstein revealed the president takes a small dose of finasteride to stimulate hair growth.
Bornstein told the New York Times that he, too, takes the drug, saying it helped him keep his shoulder-length locks and helped Trump keep his own hair.
The doctor said: ‘He has all his hair. I have all my hair.’
The news that Trump takes finasteride explained why his PSA (prostate specific antigen, produced for the cells by the prostate) is so low.
Finasteride reduces PSA levels to reduce swelling of prostate glands.
Men aged 60-69 normally have between 4.0 and 5.0ng/ml. That is higher than younger men since PSA and testosterone levels rise with age.
The number may be lower than usual if a man has prostate cancer or inflammation, causing more PSA to seep into the bloodstream.
Trump’s PSA level was 0.15, Bornstein said in two letters he’d written about Trump’s health. The first letter came out in December 2015, followed by the other letter in September 2016.
The level prompted urologists – who weren’t linked to Trump – to say he had to have received care for an enlarged prostate or prostate cancer.
Bornstein told the Times that the commander-in-chief hasn’t had an enlarged prostate nor prostate cancer, and attributed Trump’s PSA level to Propecia.
LINKS TO MENTAL HEALTH ISSUES
The researchers at Western University examined finasteride and dutasteride, another 5ARI.
‘There wasn’t a lot of good studies in this area, and it’s a very common medication for urologists to use,’ said lead author Dr Blayne Welk.
Welk’s team analyzed data from 93,197 men who were at least 66 years old when they received prescriptions for 5ARIs between 2003 and 2013, plus another 93,197 similar men who had never filled a prescription for a 5ARI.
Overall, 5ARIs were not linked with an increased risk of suicide, the researchers reported in JAMA Internal Medicine.
During the first 18 months, however, the men using 5ARIs had an 88 percent higher risk of harming themselves. That risk did not extend beyond 18 months.
Men in the 5ARI group also had a 94 percent higher risk of depression in the first 18 months, compared to men not using these drugs. Beyond 18 months, the increased risk of depression fell to 22 percent.
The type of 5ARI did not appear to significantly alter the results.
Welk cautions that the actual risk of depression and self-harm is very low.
If the drugs were actually causing these side effects – which this study wasn’t design to prove – ‘you’d need 470 men to take this medication for a full year to have a new case of depression,’ Welk said.
That number would have to be even higher to cause a new case of self-harm, since self-harm is less common than depression.
‘It is a risk potentially and patients and physicians should be aware of it,’ Welk said.
ERECTILE DYSFUNCTION RISKS
A separate study in the journal PeerJ evaluated another concern about 5ARIs – erectile dysfunction.
Drs Tina Kiguradze and William Temps of Northwestern University Feinberg School of Medicine in Chicago and colleagues found that when erectile dysfunction occurred in men taking 5ARIs for at least 180 days, the dysfunction was more likely to last at least 90 days after stopping the medication.
Erectile dysfunction, when it occurred, resolved faster in men who took the medications for shorter periods.
The proportion of men taking 5ARIs and experiencing erectile dysfunction is likely around 5 percent, according to Dr. Landon Trost, who is head of andrology and male infertility at the Mayo Clinic in Rochester, Minnesota.
But it’s not clear how many men suffer persistent erectile dysfunction after stopping 5ARIs, said Trost, who was not involved with either of the new studies.
‘I think it’s important to be educated about the potential side effects,’ he said.
Men who are already at increased risk for these potential side effects must weigh the risks and benefits of the drugs, Trost said.
He said older men taking 5ARIs for prostate problems might come to different conclusions than young men taking the pills for hair loss.
Additionally, he said, men should tell their doctors if they experience these symptoms.